Factors Associated With an Evolution in the Quality of Life of Diabetic Patients With Chronic, Wound-free Charcot Foot

NCT ID: NCT05491577

Last Updated: 2024-08-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-23

Study Completion Date

2028-01-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Charcot foot, characterized by progressive destructive damage to bone, soft tissue and tendons, involving joint dislocation in the ankle and foot, is a complication of diabetes that is still poorly understood by patients and caregivers. The clinical signs are non-specific and it is therefore largely underestimated due to a delay in diagnosis/lack of diagnosis.This study will be on a prospective multicenter cohort of patients with chronic Charcot's foot in France to evaluate the evolution of quality of life at 2 years, as well as predictive factors in order to better identify subjects with the worst outcome among this population.

Our hypothesis is that, in patients with chronic Charcot foot, the deterioration in quality of life over time is primarily related to loss of foot and ankle functionality, foot and ankle deformity and the presence of foot wounds/comorbidities/severe diabetic complications.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diabetes mellitus is a chronic disease, representing a major public health problem. An estimated 537 million people have diabetes. Charcot foot, also known as neurogenic osteoarthropathy (NAO), is one of the complications of diabetes secondary to diabetic neuropathy. It is characterized by progressive destructive damage to bone, soft tissue and tendons, involving joint dislocation in the ankle and foot. Charcot foot is a complication of diabetes that is still poorly understood by patients and caregivers, with non-specific clinical signs. It is therefore largely underestimated, since it is estimated that there is a delay in diagnosis or a lack of diagnosis in approximately 25% of cases.

The objective of our study is to conduct a prospective multicenter cohort of patients with chronic Charcot's foot in France in order to evaluate the evolution of the quality of life at 2 years, as well as its predictive factors. In this way, we will be better able to identify the subjects with the worst outcome among the chronic Charcot foot population.

Our hypothesis is that the deterioration in quality of life over time in patients with chronic Charcot foot is primarily related to loss of foot and ankle functionality, foot and ankle deformity, the presence of foot wounds and/or comorbidities or severe diabetic complications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Charcot Joint of Foot Osteoarthropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Filling in the SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire

The SF-36, FAAM-F, PHQ-9, PHQ-2 and the simplified version of the EPICES score questionnaire will all be filled in by the patients.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with Type 1 or 2 diabetes or secondary diabetes
* patient hospitalized or consulting for osteoarthropathy in its chronic stage, without wounds
* patients affiliated to or beneficiaries of a health insurance scheme.
* adult patients (≥18 years old).

Exclusion Criteria

* patients with non-diabetic osteoarthropathy of the nerves.
* patients with acute diabetic osteoarthropathy of the nerves.
* patients with a foot ulcer
* patients who have expressed opposition to participating in the study.
* patients in an exclusion period determined by another study.
* patients under court protection, guardianship or trusteeship.
* patients for whom it is impossible to give informed information.
* pregnant, parturient, or breastfeeding patients.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Nīmes

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier de Boulogne-sur-Mer

Boulogne-sur-Mer, Pas-de-Calais, France

Site Status NOT_YET_RECRUITING

Groupement Hospitalier Est, Hôpital Cardiologique Service de Diabétologie 28 Av du Doyen Lépine

Bron, , France

Site Status NOT_YET_RECRUITING

CH Sud Francilien Service de Diabétologie 40 Avenue Serge Dassault

Corbeil-Essonnes, , France

Site Status NOT_YET_RECRUITING

CHU de Grenoble Service d'Endocrinologie Allée des Sablons Les écrins

Grenoble, , France

Site Status NOT_YET_RECRUITING

Hôpital Hôtel dieu Service d'Endocrinologie 26 rue d'Harfleur

Le Creusot, , France

Site Status NOT_YET_RECRUITING

CHU Bicêtre Service d'Endocrinologie et Maladies de la reproduction 78 rue du Général Leclerc

Le Kremlin-Bicêtre, , France

Site Status RECRUITING

CH de Lens Unité de Diabétologie-Endocrinologie- Nutrition-Obésité Centre Hospitalier Dr SCHAFFNER 99 rte de La Bassée,

Lens, , France

Site Status RECRUITING

CHRU de Lille Service d'Endocrinologie Diabétologie et Métabolisme, Hôpital Claude Huriez, Rue Polonovski

Lille, , France

Site Status NOT_YET_RECRUITING

CHU de la CONCEPTION Service de Nutrition, Diabétologie, Obésité médicale, chirurgicale 47 Bd Baille

Marseille, , France

Site Status NOT_YET_RECRUITING

CHU de Montpellier Service des Maladies métaboliques 371 av. Doyen Giraud

Montpellier, , France

Site Status RECRUITING

GH Pitié Salpétrière Unité de podologie Service de Diabétologie 47-83 Bd de l'Hôpital

Paris, , France

Site Status RECRUITING

GH Paris Saint Joseph Service de Diabétologie et Endocrinologie 185 rue Raymond Losserand

Paris, , France

Site Status RECRUITING

Hôpital Cochin Service de diabétologie 123 Bd de Port Royal

Paris, , France

Site Status NOT_YET_RECRUITING

CHU de Lyon Sud Service d'Endocrinologie-Diabète-Nutrition CH Lyon Sud Pavillon médical, Bat 1B 165 chemin du Grand Revoyet

Pierre-Bénite, , France

Site Status RECRUITING

CHU Reims Service d'Endocrinologie, diabète-nutrition Rue du Général Koenig

Reims, , France

Site Status RECRUITING

Hôpitaux Universitaires de Strasbourg Service d'Endocrinologie et Diabétologie 1, place de l'hôpital,

Strasbourg, , France

Site Status NOT_YET_RECRUITING

Hôpital DRON Service de diabétologie 135 rue du Président Coty

Tourcoing, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sophie Schuldiner, Dr.

Role: CONTACT

+33 4.66.68.33.21

Anissa MEGZARI

Role: CONTACT

+33 4.66.68.42.36

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marie Lepage, Dr

Role: primary

+33 3 21 99 30 34

Myriam MORET, Dr

Role: primary

Dured DARDARI, Dr.

Role: primary

Marie Muller, Dr.

Role: primary

Haleh MOHEBBI, Dr.

Role: primary

Muriel BOURGEON, Dr

Role: primary

Fabrice DEVEMY, Dr

Role: primary

Florence BAUDOUX, Dr.

Role: primary

Rachel GRANGEOT-PATTE, Dr.

Role: primary

Ariane SULTAN, Pr

Role: primary

Georges HA VAN, Dr.

Role: primary

Olivier DUPUY, Dr.

Role: primary

Jocelyne MBEMBA, Dr

Role: primary

Julien VOUILLARMET, Dr.

Role: primary

Maud FRANCOIS, Dr.

Role: primary

Laurence KESSLER, Dr.

Role: primary

Marie CAZAUBIEL, Dr.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SI RIPH 2G : 22.01571.000083

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.